Cargando…
Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience
INTRODUCTION: Immunotherapy with nivolumab (a monoclonal antibody that targets the programmed cell death protein 1, PD1) has become the standard treatment for patients with metastatic renal cell carcinoma (mRCC) after progression to single-agent tyrosine kinase inhibitors. However, the optimal durat...
Autores principales: | Bimbatti, Davide, Dionese, Michele, Lai, Eleonora, Cavasin, Nicolò, Basso, Umberto, Mattana, Alvise, Pierantoni, Francesco, Zagonel, Vittorina, Maruzzo, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411856/ https://www.ncbi.nlm.nih.gov/pubmed/36033511 http://dx.doi.org/10.3389/fonc.2022.960751 |
Ejemplares similares
-
Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
por: Dionese, Michele, et al.
Publicado: (2023) -
Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial
por: Bimbatti, Davide, et al.
Publicado: (2022) -
Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience
por: Bimbatti, Davide, et al.
Publicado: (2023) -
Tumour Seeding After a Thoracic Biopsy for Renal Cell Carcinoma: A Case Report and a Review of the Literature
por: Michele, Dionese, et al.
Publicado: (2021) -
Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review
por: Pierantoni, Francesco, et al.
Publicado: (2019)